Protective effect of 23-hydroxybetulinic acid against doxorubicin-induced cardiotoxicity through the antioxidant activity in H9c2 cells

Abstract

Abstract: AIM: To investigate the potential protective effects of 23-hydroxybetulinic acid (23-HBA) on doxorubicin (DOX)-induced cardiotoxicity and the underlying mechanisms. METHODS: H9c2 cells were treated with DOX, 23-HBA, or their combinations, cell size and protein content were determined to evaluate the cardiac hypertrophy induced by DOX. Expression of ANP and BNP mRNA were studied by Real-time PCR. DOX-induced caspase-3 activation and apoptosis were further studied. Oxidative stress and lipid peroxidation were determined to evaluate the potential mechanism of the cardioprotective effect of 23-HBA. RESULTS: 23-HBA remarkably reduced the mRNA level of ANP and BNP induced by DOX, and reversed the cardiac hypertrophy caused by DOX treatment. Caspase-3 activity also significantly reduced when combined treated with 23-HBA and DOX compared to DOX treatment. Further studies showed that 23-HBA exerted its cardioprotective effect on DOX through decreasing the intracellular ROS and MDA amount. CONCLUSION: 23-HBA protected H9c2 cells against the cardiotoxicity of DOX, and the reduction of oxygen free radicals in cardiac myocytes may be the underlying mechanism mediating the protective effect of 23-HBA.

Key words: 23-HBA, Doxorubicin, Cardiotoxicity

CLC Number:

R965.2

HAO Gang, ZHOU Fang, LIU Jia-li, WANG Guang-ji, SANG Guo-wei, YE Wen-cai. Protective effect of 23-hydroxybetulinic acid against doxorubicin-induced cardiotoxicity through the antioxidant activity in H9c2 cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 736-743.

References

[1] Carter SK. Adriamycin-a review [J]. Natl Cancer, 1975, 55(6): 1265-1274.
[2] Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: What the cardiologist needs to know [J]. Nat Rev Cardiol, 2010, 7(10): 564-575.
[3] Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management [J]. Prog Cardiovasc Dis, 2007, 49(5): 330-352.
[4] Ye W, Zhang Q, Hsiao WW, et al. New lupane glycosides from Pulsatilla chinensis [J]. Planta Med, 2002, 68(2): 183-186.
[5] Zheng Y, Zhou F, Wu X, et al. 23-Hydroxybetulinic acid from Pulsatilla chinensis (Bunge) Regel synergizes the antitumor activities of doxorubicin in vitro and in vivo[J]. J Ethnopharmacol, 2010, 128(3): 615-622.
[6] 王广基, 郝刚, 周芳, 等. 23-HBA在制备降低阿霉素所致心脏毒性的药物中的应用, 中国: 0514113.5 [P]. 2012-01-04.
[7] Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters [J]. Nat Rev Cancer, 2002, 2(1): 48-58.
[8] 陶卫平, 蒋振旻, 吴耀贵. 吡柔比星与多柔比星的急性心脏毒性比较[J]. 医药导报, 2009, 28(9): 1216-1217.
[9] Wei J, Liu B, Wang L, et al. Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines [J]. Cancer Chemother Pharmacol, 2007, 60(5): 703-711.
[10] 谢赟, 陈寿权, 李章平. 中药对心肌损伤保护作用的研究进展[J]. 中西医结合心脑血管病杂志, 2007, 5(10): 980-981.
[11] Kimes, BW, Brandt, et al. Properties of a clonal muscle cell line from rat heart [J]. Cell Res, 1976, 98(2): 367-381.
[12] Karagiannis TC, Lin AJ, Ververis K, et al. Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes [J]. Aging (Albany NY), 2010, 2(10): 659-668.
[13] Merten KE, Jiang Y, Feng W, et al. Calcineurin activation is not necessary for Doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: involvement of the phosphoinositide 3-kinase-Akt pathway [J]. J Pharmacol Exp Ther, 2006, 319(2): 934-940.
[14] DiliĉM, Nalbantiĉ AD, Arslanagiĉ A, et al. Biphasic and monophasic pattern of brain natriuretic peptide release in acute myocardial infarction [J]. Coll Antropol, 2011, 35(1): 155-159.
[15] Wisén AG, Ekberg K, Wohlfart B, et al. Plasma ANP and BNP during exercise in patients with major depressive disorder and in healthy controls [J]. J Affect Disord, 2011, 129(1-3): 371-375.
[16] Li Z, Bing OHL, Long H, et al. Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat [J]. Am J Physiol Heart Circ Physiol, 1997, 272(41): 2313-2319.
[17] Cakir E, Yilmaz A, Demirag F, et al. Prognostic significance of micropapillary pattern in lung adenocarcinoma and expression of apoptosis-related markers: caspase-3, bcl-2, and p53 [J]. APMIS, 2011, 119(9): 574-580.
[18] Licata S, Saponiero A, Mordente A, et al. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction [J]. Chem Res Toxicol, 2000, 13(5): 414-420.
[19] Schimmel KJ, Richel DJ, van den Brink RB, et al. Cardiotoxicity of cytotoxic drugs [J]. Cancer Treat Rev, 2004, 30(2): 181-191.
[20] Kálmán Hideg, Tamás Kálai. Novel antioxidants in anthracyclines cardiotoxicity [J]. Cardiovasc Toxicol, 2007, 7(2): 160-164.
[21] 赵文英, 陈冬云, 邢文, 等. 磷酸肌酸钠对小鼠阿霉素心肌损伤的保护机制初探[J]. 中国临床药理学与治疗学, 2011, 16(3): 259-262.
[22] 黄伟, 李桂霞, 解岩, 等. 己酮可可碱对心肌保护作用及其机制研究[J]. 医药导报, 2011, 30(11): 1401-1406.